Evidence map›Paper›PMID 41530542›Full record

ArticleCommunications medicine2026

Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised

Ines Horvat-Menih, Ruth Casey, James Denholm, Gregory Hamm, Heather Hulme, John Gallon, Alixander S Khan, Joshua Kaggie, Andrew B Gill, Andrew N Priest and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ines Horvat-MenihDepartment of Radiology, University of Cambridge, Cambridge, UK. ih357@cam.ac.uk.ORCID http://orcid.org/0000-0002-1373-6944
Ruth CaseyDepartment of Endocrinology, Cambridge University NHS Foundation Trust, Cambridge, UK.
James DenholmDepartment of Radiology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-2389-3134
Gregory HammIntegrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Heather HulmeIntegrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
John GallonPredictive AI & Data, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0000-0002-5328-6298
Alixander S KhanDepartment of Radiology, University of Cambridge, Cambridge, UK.
Joshua KaggieDepartment of Radiology, University of Cambridge, Cambridge, UK.
Andrew B GillDepartment of Radiology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-9287-9563
Andrew N PriestDepartment of Radiology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-9771-4290
Joao A G DuarteDepartment of Radiology, University of Cambridge, Cambridge, UK.
Cissy YongDepartment of Surgery, University of Cambridge, Cambridge, UK.
Cara BrodieCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
James WhitworthDepartment of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre and Cancer Research UK Cambridge Centre, Cambridge, UK.
Simon T BarryBioscience TDE, Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0000-0002-8511-0588
Richard J A GoodwinPredictive AI & Data, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0000-0001-5699-8488
Shubha AnandCancer Molecular Diagnostics Laboratory (CMDL), Department of Oncology, University of Cambridge, Cambridge, UK.
Marc DoddCancer Molecular Diagnostics Laboratory (CMDL), Department of Oncology, University of Cambridge, Cambridge, UK.
Katherine HonanCancer Molecular Diagnostics Laboratory (CMDL), Department of Oncology, University of Cambridge, Cambridge, UK.
Sarah J WelshPinto Medical Consultancy, Cambridge, UK.
Anne Y WarrenDepartment of Pathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Tevita AhoDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Grant D StewartDepartment of Surgery, University of Cambridge, Cambridge, UK.
Thomas J MitchellDepartment of Surgery, University of Cambridge, Cambridge, UK.
Mary A McLeanDepartment of Radiology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-3752-0179
Ferdia A GallagherDepartment of Radiology, University of Cambridge, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFumarate hydratase-deficient renal cell carcinoma (FHd-RCC) is a rare and aggressive renal cancer subtype characterised by increased fumarate accumulation and upregulated lactate production. Renal tumours demonstrate significant intratumoral metabolic heterogeneity, which may contribute to treatment failure. Emerging non-invasive metabolic imaging techniques have clinical potential to more accurately phenotype tumour metabolism and its heterogeneity.

methodsIn this case study we have used hyperpolarised

resultsHP

conclusionsThis study shows the potential of metabolic HP

Identifiers

PMID41530542
PMCPMC12894661

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.